AED evaluated
|
Pregabalin
|
Topiramate
|
Felbamate
|
2
nd
AED
|
PB (9 dogs)
|
PB (10 dogs)
|
PB (6 dogs)
|
3
rd
AED
|
PBr (8 dogs)
|
PBr (8 dogs)
|
-
|
4
th
AED
|
-
|
LEV (1 dogs)
|
-
|
No of dogs
|
9
|
10
|
6
|
Period of treatment (months)
|
3
|
6-15
|
median, 9
|
Dose of AED(s) (mg/kg)
|
Pregabalin: 2 PO TID (dose was increased up to until 3–4 PO TID); PB and PBr: NA but were within normal reference values
|
TPM: 5 PO BID for 2 m, then 10 PO BID for 2 m and then 10 PO TID for 2 m; PB and PBr and LEV: NA but were within normal reference values
|
Felbamate: median, 63 (initial dose) and 77 (final dose) PO SID; PB: 3.75 PO BID (stopped 2 m after felbamate started)
|
Pre-treatment SF (seizures/month)
|
median, 4.3; mean, 4.2; range, 2–6.3 (recorded over a period of 3 m)
|
median, 3.75; range, 2–9 (recorded over a period of 2 m)
|
median, 3.75 (recorded over a period of median 3.8 m)
|
Post-treatment SF (seizures/month)
|
median 1.7; mean 1.8; range 0.7-3.3
|
Range, 4·3 ± 2·5-4· 7 ± 5·0 (recorded at the 6th m)
|
2 seizures (in total)
|
No of dogs that were failures
|
-
|
3/10 (30%)
|
-
|
No of dogs with >0% - <50% reduction in SF
|
2/9 (22%)
|
2/10 (20%)
|
-
|
No of dogs with ≥50% - <100% reduction in SF
|
7/9 (78%)
|
3/10 (30%)
|
4/6 (66%)
|
No of dogs with 100% reduction in SF
|
-
|
2/10 (20%)
|
2/6 (34%)
|
No of dogs with >30% reduction in SF
|
7/9 (78%)
|
6/10 (60%)
|
6/6 (100%)
|
95% CI successfully treated cases
|
51% - 100%
|
19% - 81%
|
100%
|
Overall evidence for/against recommending the use of an AED
|
Insufficient evidence for recommending the use of pregabalin as an adjunct AED.
|
Insufficient evidence for recommending the use of topiramate as an adjunct AED.
|
Insufficient evidence for recommending the use of felbamate as an adjunct AED.
|